{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:27:37Z","timestamp":1786771657000,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the outcomes of Preserflo MicroShunt (PMS) implantation in pigmentary glaucoma (PG) and compare them with a matched primary open-angle glaucoma (POAG) cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective study included consecutive patients with PG undergoing PMS implantation between 2021 and 2025 at a single tertiary centre. A 1:2 propensity score\u2013matched POAG control group was created based on demographic and clinical baseline characteristics. The primary outcome was surgical success at 2 years, defined as \u2265\u200920% IOP reduction and IOP\u2009\u2264\u200918 mmHg without hypotony-related complications. Secondary outcomes included stricter success criteria, IOP reduction, medication use, revisions, and complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-one PG patients were matched to 62 POAG patients. Median follow-up was 28 and 32 months, respectively. PMS implantation resulted in significant and sustained IOP reduction in both groups (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), with no significant differences between PG and POAG at any time point. Median IOP at 2 years was 14 mmHg in both groups. IOP-lowering agents decreased to a median of 0 in both groups, with most patients remaining medication-free. Complete success at 2 years was 61% in PG and 49% in POAG (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.35). Bleb revisions were required in 45% and 52%. Outcomes across stricter success criteria and complications were not significantly different.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PMS implantation in PG was not associated with significantly different efficacy, safety and revision burden compared with POAG. The distinct pathophysiology of PG does not appear to adversely affect surgical outcomes, supporting the PMS as a viable treatment option in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07460-5","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:55:39Z","timestamp":1786769739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preserflo microshunt outcomes in pigmentary glaucoma: a propensity score\u2013matched comparison with primary open-angle glaucoma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3375-702X","authenticated-orcid":false,"given":"Emil","family":"Nasyrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogomil","family":"Voykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"7460_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0039-6257(93)90008-u","volume":"37","author":"SM Farrar","year":"1993","unstructured":"Farrar SM, Shields MB (1993) Current concepts in pigmentary glaucoma. Surv Ophthalmol 37:233\u2013252. https:\/\/doi.org\/10.1016\/0039-6257(93)90008-u","journal-title":"Surv Ophthalmol"},{"key":"7460_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00417-022-05817-0","volume":"261","author":"R Pang","year":"2023","unstructured":"Pang R, Labisi SA, Wang N (2023) Pigment dispersion syndrome and pigmentary glaucoma: overview and racial disparities. Graefes Arch Clin Exp Ophthalmol 261:601\u2013614. https:\/\/doi.org\/10.1007\/s00417-022-05817-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7460_CR3","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ophtha.2007.06.028","volume":"114","author":"F Grehn","year":"2007","unstructured":"Grehn F, Holl\u00f3 G, Khaw P, Overton B, Wilson R, Vogel R, Smith Z (2007) Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152. Ophthalmology 114:1831\u20131838. https:\/\/doi.org\/10.1016\/j.ophtha.2007.06.028","journal-title":"Ophthalmology"},{"key":"7460_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.4103\/0366-6999.182825","volume":"129","author":"GP Qing","year":"2016","unstructured":"Qing GP, Wang NL, Wang T, Chen H, Mou DP (2016) Long-term Efficacy of Trabeculectomy on Chinese Patients with Pigmentary Glaucoma: A Prospective Case Series Observational Study. Chin Med J (Engl) 129:1268\u20131272. https:\/\/doi.org\/10.4103\/0366-6999.182825","journal-title":"Chin Med J (Engl)"},{"key":"7460_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ophtha.2023.09.023","volume":"131","author":"JF Panarelli","year":"2024","unstructured":"Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT (2024) Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study. Ophthalmology 131:266\u2013276. https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.023","journal-title":"Ophthalmology"},{"key":"7460_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajo.2023.11.011","volume":"259","author":"A Rabiolo","year":"2024","unstructured":"Rabiolo A, Toscani R, Sacchi M, Destefanis P, Bettin P, Ciampi C, Clemente A, Cutolo CA, Mercieca K, Iester M, Traverso CE, Di Maita M, Li Calzi G, Nucci P, Bandello F, Triolo G, De Cill\u00e0 S (2024) Risk Factors for Failure in Glaucoma Patients Undergoing Microshunt Implantation. Am J Ophthalmol 259:117\u2013130. https:\/\/doi.org\/10.1016\/j.ajo.2023.11.011","journal-title":"Am J Ophthalmol"},{"key":"7460_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-026-07135-1","author":"M Garc\u00eda-Berm\u00fadez","year":"2026","unstructured":"Garc\u00eda-Berm\u00fadez M, Garc\u00eda-Bardera J, Pascual-Santiago MA, Robles-Amor P, Morales-Fern\u00e1ndez L, G\u00fcemes-Villahoz N, M\u00e9ndez-Hern\u00e1ndez CD, Garc\u00eda-Sa\u00e9nz S, Mart\u00ednez-de-la-Casa JM, Garc\u00eda-Feijoo J (2026) Functional assessment of the Preserflo MicroShunt implant in pigmentary glaucoma: 2 years follow-up. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-026-07135-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7460_CR8","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/s0002-9394(02)02289-4","volume":"135","author":"Y Siddiqui","year":"2003","unstructured":"Siddiqui Y, Ten Hulzen RD, Cameron JD, Hodge DO, Johnson DH (2003) What is the risk of developing pigmentary glaucoma from pigment dispersion syndrome? Am J Ophthalmol 135:794\u2013799. https:\/\/doi.org\/10.1016\/s0002-9394(02)02289-4","journal-title":"Am J Ophthalmol"},{"key":"7460_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2436101","author":"E Nasyrov","year":"2024","unstructured":"Nasyrov E, Seppelfricke C, Doycheva D, Gassel CJ, Merle DA, Voykov B (2024) Preserflo microshunt implantation for glaucoma secondary to viral and juvenile idiopathic arthritis-related anterior uveitis. Ocul Immunol Inflamm. https:\/\/doi.org\/10.1080\/09273948.2024.2436101","journal-title":"Ocul Immunol Inflamm"},{"key":"7460_CR10","volume-title":"Guidelines on design and reporting of glaucoma surgical trials","author":"T Shaarawy","year":"2009","unstructured":"Shaarawy T, Sheerwood MB, Grehn F (2009) Guidelines on design and reporting of glaucoma surgical trials. Kugler, Amsterdam, The Netherlands"},{"key":"7460_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2024.01.008","volume":"131","author":"A Rabiolo","year":"2024","unstructured":"Rabiolo A, Triolo G, Khaliliyeh D, Jin SW, Morales E, Ghirardi A, Anand N, Montesano G, Virgili G, Caprioli J, De Cill\u00e0 S (2024) Hypotony Failure Criteria in Glaucoma Surgical Studies and Their Influence on Surgery Success. Ophthalmology 131:803\u2013814. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.008","journal-title":"Ophthalmology"},{"key":"7460_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2023-egsguidelines","volume":"107","author":"L Abegao Pinto","year":"2023","unstructured":"Abegao Pinto L, Sunaric M\u00e9gevand G, Stalmans I, Azuara-Blanco A, Bron A, Garcia Feijoo J, Garway Heath T, Grehn F, King A, Kirwan J, McNaught A, Mercieca K, Oddone F, Saldanha I, Spaeth G, Topouzis F, Enrico Traverso C, Tuulonen A (2023) European Glaucoma Society - A guide on surgical innovation for glaucoma. Br J Ophthalmol 107:1\u2013114. https:\/\/doi.org\/10.1136\/bjophthalmol-2023-egsguidelines","journal-title":"Br J Ophthalmol"},{"key":"7460_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC (2014) A comparison of 12 algorithms for matching on the propensity score. Stat Med 33:1057\u20131069. https:\/\/doi.org\/10.1002\/sim.6004","journal-title":"Stat Med"},{"key":"7460_CR14","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"7460_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/jep.12072","volume":"19","author":"A Linden","year":"2013","unstructured":"Linden A, Samuels SJ (2013) Using balance statistics to determine the optimal number of controls in matching studies. J Eval Clin Pract 19:968\u2013975. https:\/\/doi.org\/10.1111\/jep.12072","journal-title":"J Eval Clin Pract"},{"key":"7460_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1212\/wnl.0000000000012777","volume":"97","author":"PC Austin","year":"2021","unstructured":"Austin PC, Yu AYX, Vyas MV, Kapral MK (2021) Applying Propensity Score Methods in Clinical Research in Neurology. Neurology 97:856\u2013863. https:\/\/doi.org\/10.1212\/wnl.0000000000012777","journal-title":"Neurology"},{"key":"7460_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/1475-6773.12182","volume":"49","author":"MM Garrido","year":"2014","unstructured":"Garrido MM, Kelley AS, Paris J, Roza K, Meier DE, Morrison RS, Aldridge MD (2014) Methods for constructing and assessing propensity scores. Health Serv Res 49:1701\u20131720. https:\/\/doi.org\/10.1111\/1475-6773.12182","journal-title":"Health Serv Res"},{"key":"7460_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00417-025-07108-w","volume":"264","author":"CEH Fang","year":"2026","unstructured":"Fang CEH, Fea AM, Economou MA, Fenerty C, Yau K, Yu J, Au L (2026) Preserflo MicroShunt in refractory glaucoma: multicentre european results with up to three years of follow-up. Graefes Arch Clin Exp Ophthalmol 264:1391\u20131399. https:\/\/doi.org\/10.1007\/s00417-025-07108-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7460_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-026-07199-z","author":"K Klabe","year":"2026","unstructured":"Klabe K, Werth JP, Kaymak H, Fricke A (2026) Clinical outcomes of Preserflo MicroShunt implant procedure in open\u2013angle glaucoma patients - a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-026-07199-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7460_CR20","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s00417-025-06928-0","volume":"263","author":"A Skowronski","year":"2025","unstructured":"Skowronski A, Habbe KJ, Kontopoulou K, Kohlhaas M, Fili S (2025) 3-year real-world outcomes of standalone PreserFlo MicroShunt implantation - effectiveness and safety profile. Graefes Arch Clin Exp Ophthalmol 263:3179\u20133189. https:\/\/doi.org\/10.1007\/s00417-025-06928-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7460_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/11206721241261093","volume":"35","author":"CJ Gassel","year":"2025","unstructured":"Gassel CJ, Nasyrov E, Wenzel DA, Voykov B (2025) XEN45 gel stent in the treatment of pigmentary glaucoma: A two-year follow-up. Eur J Ophthalmol 35:172\u2013180. https:\/\/doi.org\/10.1177\/11206721241261093","journal-title":"Eur J Ophthalmol"},{"key":"7460_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134474","author":"JJ Storp","year":"2023","unstructured":"Storp JJ, Vietmeier FE, Mert\u00e9 RL, Koch R, Zimmermann JA, Eter N, Br\u00fccher VC (2023) Long-term outcomes of the PRESERFLO MicroShunt implant in a heterogeneous glaucoma cohort. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12134474","journal-title":"J Clin Med"},{"key":"7460_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/bjophthalmol-2021-320631","volume":"107","author":"A Tanner","year":"2023","unstructured":"Tanner A, Haddad F, Fajardo-Sanchez J, Nguyen E, Thong KX, Ah-Moye S, Perl N, Abu-Bakra M, Kulkarni A, Trikha S, Lascaratos G, Parnell M, Kailani O, King AJ, Agrawal P, Stead R, Giannouladis K, Rodrigues I, Goyal S, Hysi PG, Lim S, Yu-Wai-Man C (2023) One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis. Br J Ophthalmol 107:1104\u20131111. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-320631","journal-title":"Br J Ophthalmol"},{"key":"7460_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237086","author":"A Majoulet","year":"2022","unstructured":"Majoulet A, Scemla B, Hamard P, Brasnu E, Hage A, Baudouin C, Labb\u00e9 A (2022) Safety and efficacy of the Preserflo(\u00ae) microshunt in refractory glaucoma: a one-year study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11237086","journal-title":"J Clin Med"},{"key":"7460_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-026-07255-8","author":"CJ Wenzel","year":"2026","unstructured":"Wenzel CJ, Pagonidou C, Wenzel DA, Druchkiv V, Nasyrov E, Voykov B (2026) Predicting bleb revision after XEN gel stent surgery in a real-world open-angle glaucoma cohort. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-026-07255-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7460_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ajo.2025.11.045","volume":"283","author":"M Jung","year":"2026","unstructured":"Jung M, Kong YZ, Ansari AS, Lawlor M, Tan JCK (2026) Risk Factors for Failure in Minimally Invasive Bleb Surgery: A Systematic Review. Am J Ophthalmol 283:55\u201371. https:\/\/doi.org\/10.1016\/j.ajo.2025.11.045","journal-title":"Am J Ophthalmol"},{"key":"7460_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/ijg.0000000000002246","volume":"32","author":"A Strzalkowska","year":"2023","unstructured":"Strzalkowska A, Strzalkowski P, Hoffmann EM, Pfeiffer N, Schuster AK (2023) Outcomes of Open Bleb Revision After PreserFlo MicroShunt Failure in Patients With Glaucoma. J Glaucoma 32:681\u2013685. https:\/\/doi.org\/10.1097\/ijg.0000000000002246","journal-title":"J Glaucoma"},{"key":"7460_CR28","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41433-025-03707-3","volume":"39","author":"LMJ Scheres","year":"2025","unstructured":"Scheres LMJ, Kujovic-Aleksov S, Winkens B, de Crom R, Webers CAB, Beckers HJM (2025) Five-year follow-up with the PreserFlo MicroShunt for open-angle glaucoma. Eye (Lond) 39:1540\u20131546. https:\/\/doi.org\/10.1038\/s41433-025-03707-3","journal-title":"Eye (Lond)"},{"key":"7460_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ceo.12737","volume":"44","author":"H Akil","year":"2016","unstructured":"Akil H, Chopra V, Huang A, Loewen N, Noguchi J, Francis BA (2016) Clinical results of ab interno trabeculotomy using the Trabectome in patients with pigmentary glaucoma compared to primary open angle glaucoma. Clin Exp Ophthalmol 44:563\u2013569. https:\/\/doi.org\/10.1111\/ceo.12737","journal-title":"Clin Exp Ophthalmol"},{"key":"7460_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9124024","author":"P Brusini","year":"2020","unstructured":"Brusini P, Papa V (2020) Canaloplasty in pigmentary glaucoma: long-term outcomes and proposal of a new hypothesis on its intraocular pressure lowering mechanism. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9124024","journal-title":"J Clin Med"},{"key":"7460_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/aos.70018","author":"E Nasyrov","year":"2025","unstructured":"Nasyrov E, Kommerell I, Schleicher I, Merle DA, Wenzel CJ, Voykov B (2025) Incidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation. Acta Ophthalmol DOI. https:\/\/doi.org\/10.1111\/aos.70018","journal-title":"Acta Ophthalmol DOI"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07460-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07460-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07460-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:55:41Z","timestamp":1786769741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07460-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":31,"alternative-id":["7460"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07460-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the University of Tuebingen (project number 074\/2023BO2). Patient consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EN has received a travel grant unrelated to this work from Santen. BV has received speaker honoraria and consultancy fees from Santen and AbbVie unrelated to this work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}